Our Pipeline

Rich and diverse

Our numbers speak volumes. With more than 120 biologics in R&D and 40 products in clinical development, we have one of the strongest, most robust pipelines in the industry.


Cardiovascular and Metabolic diseases

Phase 1

Phase 1

  • MEDI8111 trauma/bleeding

Phase 2

Phase 2

  • MEDI0382 diabetes/obesity
  • MEDI4166 diabetes/cardiovascular
  • MEDI6012 ACS

Phase 3

Phase 3

Oncology

Phase 1

Phase 1

  • MEDI-565 solid tumours
  • MEDI0562 solid tumours
  • MEDI0680 solid tumours
  • MEDI1873 solid tumours
  • MEDI4276 solid tumours
  • MEDI9197 solid tumours
  • MEDI9447 solid tumours
  • durvalumab + AZD1775 solid tumours
  • durvalumab + Iressa NSCLC
  • durvalumab + MEDI0562 solid tumours
  • durvalumab + MEDI9447 solid tumours
  • durvalumab + dabrafenib + trametinib melanoma
  • durvalumab + monalizumab solid tumours
  • durvalumab + selumetinib solid tumours
  • durvalumab + tremelimumab solid tumours
  • durvalumab or durvalumab + (tremelimumab or AZD9150) diffuse large B-cell lymphoma
  • tremelimumab + MEDI0562 solid tumours

Phase 2

Phase 2

  • MEDI-573 metastatic breast cancer
  • durvalumab solid tumours
  • durvalumab + AZD5069 durvalumab + AZD9150 HNSCC
  • durvalumab + MEDI0680 solid tumours
  • durvalumab + tremelimumab Hepatocellular carcinoma (liver cancer)
  • durvalumab + tremelimumab gastric cancer

Phase 3

Phase 3

  • durvalumab ≥2nd-line advanced bladder cancer
  • durvalumab PACIFIC stage III NSCLC
  • durvalumab + tremelimumab ARCTIC 3rd-line NSCLC
  • durvalumab + tremelimumab DANUBE 1st-line bladder
  • durvalumab + tremelimumab EAGLE 2nd-line SCCHN
  • durvalumab + tremelimumab KESTREL 1st-line SCCHN
  • durvalumab + tremelimumab MYSTIC 1st-line NSCLC
  • durvalumab + tremelimumab NEPTUNE 1st-line NSCLC
  • moxetumomab pasudotox PLAIT hairy cell leukaemia

Respiratory

Phase 1

Phase 1

  • MEDI9314 atopic dermatitis

Phase 2

Phase 2

  • AZD9412 asthma/COPD
  • tezepelumab asthma/atopic dermatitis

Phase 3

Phase 3

  • benralizumab CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • benralizumab TERRANOVA GALATHEA COPD
  • tralokinumab STRATOS 1,2 TROPOS MESOS severe asthma

Other

Phase 1

Phase 1

  • MEDI0700 systemic lupus erythematosus
  • MEDI1814 Alzheimer’s disease
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI7352 osteoarthritis pain
  • MEDI7734 myositis
  • anifrolumab systemic lupus erythematosus (subcutaneous)

Phase 2

Phase 2

  • MEDI3902 prevention of nosocomial pseudomonas pneumonia
  • MEDI4893 hospital-acquired pneumonia/serious S. aureus infection
  • MEDI5872 primary Sjögren’s syndrome
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • inebilizumab neuromyelitis optica
  • mavrilimumab rheumatoid arthritis

Phase 3

Phase 3

  • anifrolumab TULIP systemic lupus erythematosus

Terminations

  • durvalumab HAWK solid tumours
  • durvalumab + tremelimumab CONDOR 2nd-line SCCHN (PD-L1 negative)
  • durvalumab + tremelimumab ALPS metastatic pancreatic ductal carcinoma
  • durvalumab solid tumours
  • MEDI2070 Crohn’s disease
  • MEDI7510 prevention of RSV disease in older adults

AstraZeneca Pipeline

Together with AstraZeneca, we have an exciting and balanced pipeline underpinned by great science. Uniquely positioned with both large and small molecules, the development pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.